



12<sup>th</sup> October 2022

The Manager,  
Listing Compliance Department,  
**National Stock Exchange of India Ltd,**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400051

**Symbol: SAKAR**

Corporate Office :  
406, Silver Oaks Comm. Complex,  
Opp. Arun Society, Paldi,  
Ahmedabad-380 007. Gujarat, India.  
Phone : 079-26584655  
Fax : 079-26588054  
CIN No. : L24231GJ2004PLC043861  
E-mail : info@sakarhealthcare.com  
Web : www.sakarhealthcare.com

**Subject: Announcement under Regulation 30 (LODR) - Sakar Healthcare Oncology unit receives WHO - GMP approval (Oral Solid Dosage-Tablet, Capsule & API block)**

Dear All,

Sakar Healthcare is pleased to share that both their oncology Oral Solid Dosage (OSD) and Active Pharmaceutical Ingredient (API) manufacturing blocks, which are a part of its research-driven API-integrated oncology formulation manufacturing unit located at Bavla, Gujarat, India, have received WHO GMP approval from Food & Drugs Control Administration, Gujarat. The regulatory authority has certified both the above mentioned units complying to Good Manufacturing Practices (GMP) with cytotoxic category of drugs.

This certification will enable Sakar Oncology unit:

- Trigger for manufacturing unit audits (OSD finished formulations and APIs) by regulatory bodies of multiple countries, a pre-requisite to export these products
- To prepare dossiers with CoPP for the product range in OSD category (tablets, Capsules) of Sakar and then after file in respective regions/countries to gain product registrations (Marketing Authorizations) that would allow export of the products of Sakar
- To proceed with process validation with complete documentation for approval pertaining to APIs manufactured at Sakar bulk drug manufacturing site
- To utilize glass-line reactors/assembly to develop and supply high potent API (HPAPI) to prospects and partners in anti-cancer segment
- To manufacture and supply the big brands in tablets/capsules for renown players in the segment at international level

Thus, with WHO GMP approval both the Oral Solid Dosage and Active Pharmaceutical Ingredient (Bulk Drug) units are ready to prepare for organized business following stringent regulatory guidelines which will add-on values in times to come.

This is for your information, records and meeting the disclosure requirements under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Thanking you,

Yours faithfully,  
**for SAKAR HEALTHCARE LIMITED**

**BHARAT SONI**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**